Esperion, Daiichi: $125 M Amendment to Collaboration, Including Resolution of Pending Litigation

 – Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet –

– Amendment also includes transfer of certain manufacturing and supply rights to DSE and expansion of collaboration in Europe and other territories –

https://www.globenewswire.com/news-release/2024/01/03/2803174/0/en/Esperion-and-Daiichi-Sankyo-Europe-Announce-125-Million-Amendment-to-Their-Collaboration-Including-Resolution-of-Pending-Litigation.html